Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 29c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.54), $0.29 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $374.55 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating